Amended in Senate May 28, 2013

Amended in Senate May 24, 2013

Amended in Senate May 14, 2013

Amended in Senate May 1, 2013

Senate BillNo. 809


Introduced by Senators DeSaulnier and Steinberg

(Coauthors: Senators Hancock, Lieu, Pavley, and Price)

(Coauthor: Assembly Member Blumenfield)

February 22, 2013


An act to add Sections 805.8 and 2196.8 to the Business and Professions Code,begin insert andend insert to amend Sectionsbegin delete 11165end deletebegin insert 11164.1, 11165,end insert and 11165.1begin delete ofend deletebegin insert of, and to add Section 11165.4 to,end insert the Health and Safety Code,begin delete and to add Part 21 (commencing with Section 42001) to Division 2 of the Revenue and Taxation Code,end delete relating to controlled substances, and declaring the urgency thereof, to take effect immediately.

LEGISLATIVE COUNSEL’S DIGEST

SB 809, as amended, DeSaulnier. Controlled substances: reporting.

(1) Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe or dispense these controlled substances.

Existing law requires dispensing pharmacies and clinics to report, on a weekly basis, specified information for each prescription of Schedule II, Schedule III, or Schedule IV controlled substances, to the department, as specified.

This bill would establish the CURES Fund within the State Treasury to receive funds to be allocated, upon appropriation by the Legislature, to the Department of Justice for the purposes of funding CURES, and would make related findings and declarations.

This bill would require the Medical Board of California, the Dental Board of California, the California State Board of Pharmacy, the Veterinary Medical Board, the Board of Registered Nursing, the Physician Assistant Committee of the Medical Board of California, the Osteopathic Medical Board of California, the Naturopathic Medicine Committee of the Osteopathic Medical Board of California, the State Board of Optometry, and the California Board of Podiatric Medicine to charge practitioners under their supervision who are authorized to prescribe, order, administer, furnish, or dispense controlled substances a fee of up to 1.16% of the renewal fee that the licensee was subject to as of July 1, 2013, the proceeds of which would be deposited into the CURES Fund for support of CURES, as specified. This bill would also require the California State Board of Pharmacy to charge wholesalers, nonresident wholesalers, and veterinary food-animal drug retailers under their supervision a fee of up to 1.16% of the renewal fee that the wholesaler, nonresident wholesaler, or veterinary food-animal drug retailer was subject to as of July 1, 2013, the proceeds of which would be deposited into the CURES Fund for support of CURES, as specified. The bill would require each of these fees to be due and payable at the time the license is renewed and require the fee to be submitted with the renewal fee.begin insert The bill would also permit specified insurers, end insertbegin inserthealth care service plans, end insertbegin insertand qualified manufacturers, end insertbegin insertto voluntarily contribute to the CURES Fund, as described.end insert

(2) Existing law requires the Medical Board of California to periodically develop and disseminate information and educational materials regarding various subjects, including pain management techniques, to each licensed physician and surgeon and to each general acute care hospital in California.

This bill would additionally require the board to periodically develop and disseminate to each licensed physician and surgeon and to each general acute care hospital in California information and educational materials relating to the assessment of a patient’s risk of abusing or diverting controlled substances and information relating to CURES.

(3) Existing law permits a licensed health care practitioner, as specified, or a pharmacist to apply to the Department of Justice to obtain approval to access information stored on the Internet regarding the controlled substance history of a patient under his or her care. Existing law also authorizes the Department of Justice to provide the history of controlled substances dispensed to an individual to licensed health care practitioners, pharmacists, or both, providing care or services to the individual.

This bill would require licensed health care practitioners, as specified, and pharmacists to apply to the Department of Justice to obtain approval to access information stored on the Internet regarding the controlled substance history of a patient under his or her care, and, upon the happening of specified events, to be strongly encouraged to access and consult that information prior to prescribing or dispensing Schedule II, Schedule III, or Schedule IV controlled substances. The bill would make other related and conforming changes.

begin delete

(4) Existing law imposes various taxes, including taxes on the privilege of engaging in certain activities. The Fee Collection Procedures Law, the violation of which is a crime, provides procedures for the collection of certain fees and surcharges.

end delete
begin delete

This bill would impose a tax upon qualified manufacturers, as defined, beginning January 1, 2015. The tax would be collected by the State Board of Equalization pursuant to the procedures set forth in the Fee Collection Procedures Law. The bill would require the board to deposit all taxes, penalties, and interest collected pursuant to these provisions in the CURES Fund, as provided. This bill would also allow specified insurers, as defined, and health care service plans, as defined, to voluntarily contribute to the CURES Fund, as described. Because this bill would expand application of the Fee Collection Procedures Law, the violation of which is a crime, it would impose a state-mandated local program.

end delete
begin delete

(5) The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

end delete
begin delete

This bill would provide that no reimbursement is required by this act for a specified reason.

end delete
begin delete

(6)

end delete

begin insert(end insertbegin insert4)end insert This bill would declare that it is to take effect immediately as an urgency statute.

Vote: 23. Appropriation: no. Fiscal committee: yes. State-mandated local program: begin deleteyes end deletebegin insertnoend insert.

The people of the State of California do enact as follows:

P4    1

SECTION 1.  

The Legislature finds and declares all of the
2following:

3(a) The Controlled Substance Utilization Review and Evaluation
4System (CURES) is a valuable preventive, investigative, and
5educational tool for health care providers, regulatory boards,
6educational researchers, and law enforcement. Recent budget cuts
7to the Attorney General’s Division of Law Enforcement have
8resulted in insufficient funding to support the CURES Prescription
9Drug Monitoring Program (PDMP). The PDMP is necessary to
10ensure health care professionals have the necessary data to make
11informed treatment decisions and to allow law enforcement to
12investigate diversion of prescription drugs. Without a dedicated
13funding source, the CURES PDMP is not sustainable.

14(b) Each year CURES responds to more than 800,000 requests
15from practitioners and pharmacists regarding all of the following:

16(1) Helping identify and deter drug abuse and diversion of
17prescription drugs through accurate and rapid tracking of Schedule
18II, Schedule III, and Schedule IV controlled substances.

19(2) Helping practitioners make better prescribing decisions.

20(3) Helping reduce misuse, abuse, and trafficking of those drugs.

21(c) Schedule II, Schedule III, and Schedule IV controlled
22substances have had deleterious effects on private and public
23interests, including the misuse, abuse, and trafficking in dangerous
24prescription medications resulting in injury and death. It is the
25intent of the Legislature to work with stakeholders to fully fund
26the operation of CURES which seeks to mitigate those deleterious
27 effects and serve as a tool for ensuring safe patient care, and which
28has proven to be a cost-effective tool to help reduce the misuse,
29abuse, and trafficking of those drugs.

30(d) The following goals are critical to increase the effectiveness
31and functionality of CURES:

32(1) Upgrading the PDMP so that it is capable of accepting
33real-time updates and is accessible in real-time, 24 hours a day,
34seven days a week.

P5    1(2) Upgrading all prescription drug monitoring programs in
2California so that they are capable of operating in conjunction with
3all national prescription drug monitoring programs.

4(3) Providing subscribers to prescription drug monitoring
5programs access to information relating to controlled substances
6dispensed in California, including those dispensed through the
7federal Department of Veterans’ Affairs, the Indian Health Service,
8the Department of Defense, and any other entity with authority to
9dispense controlled substances in California.

10(4) Upgrading the PDMP so that it is capable of accepting
11electronic prescriptions, thereby enabling more reliable, complete,
12and timely prescription monitoring.

13

SEC. 2.  

Section 805.8 is added to the Business and Professions
14Code
, to read:

15

805.8.  

(a) (1) In addition to the fees charged for licensure,
16certification, and renewal, at the time those fees are charged, the
17Medical Board of California, the Dental Board of California, the
18California State Board of Pharmacy, the Veterinary Medical Board,
19the Board of Registered Nursing, the Physician Assistant
20Committee of the Medical Board of California, the Osteopathic
21Medical Board of California, the Naturopathic Medicine Committee
22of the Osteopathic Medical Board of California, the State Board
23of Optometry, and the California Board of Podiatric Medicine shall
24charge each licensee authorized pursuant to Section 11150 of the
25Health and Safety Code to prescribe, order, administer, furnish,
26or dispense Schedule II, Schedule III, or Schedule IV controlled
27substances a fee of up to 1.16 percent of the renewal fee that the
28licensee was subject to as of July 1, 2013, to be assessed annually.
29This fee shall be due and payable at the time the licensee renews
30his or her license and shall be submitted with the licensee’s renewal
31fee. In no case shall this fee exceed the reasonable costs associated
32with operating and maintaining CURES for the purpose of
33regulating prescribers and dispensers of controlled substances
34licensed or certificated by these boards.

35(2) In addition to the fees charged for licensure, certification,
36and renewal, at the time those fees are charged, the California State
37Board of Pharmacy shall charge wholesalers and nonresident
38wholesalers of dangerous drugs, licensed pursuant to Article 11
39(commencing with Section 4160) of Chapter 9, a fee of up to 1.16
40percent of the renewal fee that the wholesaler or nonresident
P6    1wholesaler was subject to as of July 1, 2013, to be assessed
2annually. This fee shall be due and payable at the time the
3wholesaler or nonresident wholesaler renews its license and shall
4be submitted with the wholesaler’s or nonresident wholesaler’s
5renewal fee. In no case shall this fee exceed the reasonable costs
6associated with operating and maintaining CURES for the purpose
7of regulating wholesalers and nonresident wholesalers of dangerous
8drugs licensed or certificated by that board.

9(3) In addition to the fees charged for licensure, certification,
10and renewal, at the time those fees are charged, the California State
11Board of Pharmacy shall charge veterinary food-animal drug
12retailers, licensed pursuant to Article 15 (commencing with Section
134196) of Chapter 9, a fee of up to 1.16 percent of the renewal fee
14that the drug retailer was subject to as of July 1, 2013, to be
15assessed annually. This fee shall be due and payable at the time
16the drug retailer renews its license and shall be submitted with the
17drug retailers’ renewal fee. In no case shall this fee exceed the
18reasonable costs associated with operating and maintaining CURES
19for the purpose of regulating veterinary food-animal drug retailers
20licensed or certificated by that board.

21(b) The funds collected pursuant to subdivision (a) shall be
22deposited in the CURES accounts, which are hereby created, within
23the Contingent Fund of the Medical Board of California, the State
24Dentistry Fund, the Pharmacy Board Contingent Fund, the
25Veterinary Medical Board Contingent Fund, the Board of
26Registered Nursing Fund, the Naturopathic Doctor’s Fund, the
27Osteopathic Medical Board of California Contingent Fund, the
28Optometry Fund, and the Board of Podiatric Medicine Fund.
29Moneys in the CURES accounts of each of those funds shall, upon
30appropriation by the Legislature, be available to the Department
31of Justice solely for operating and maintaining CURES for the
32purposes of regulating prescribers and dispensers of controlled
33substances. All moneys received by the Department of Justice
34pursuant to this section shall be deposited in the CURES Fund
35described in Section 11165 of the Health and Safety Code.

36

SEC. 3.  

Section 2196.8 is added to the Business and Professions
37Code
, to read:

38

2196.8.  

The board shall periodically develop and disseminate
39information and educational material regarding assessing a patient’s
40risk of abusing or diverting controlled substances and information
P7    1relating to the Controlled Substance Utilization Review and
2Evaluation System (CURES), described in Section 11165 of the
3Health and Safety Code, to each licensed physician and surgeon
4and to each general acute care hospital in this state. The board
5shall consult with the State Department of Health Care Services
6and the Department of Justice in developing the materials to be
7distributed pursuant to this section.

8begin insert

begin insertSEC. 4.end insert  

end insert

begin insertSection 11164.1 of the end insertbegin insertHealth and Safety Codeend insertbegin insert is
9amended to read:end insert

10

11164.1.  

(a)  (1)  Notwithstanding any other provision of law,
11a prescription for a controlled substance issued by a prescriber in
12another state for delivery to a patient in another state may be
13dispensed by a California pharmacy, if the prescription conforms
14with the requirements for controlled substance prescriptions in the
15state in which the controlled substance was prescribed.

16(2)  All prescriptions for Schedule II and Schedule III controlled
17substances dispensed pursuant to this subdivision shall be reported
18by the dispensing pharmacy to the Department of Justice in the
19manner prescribed by subdivisionbegin delete (d)end deletebegin insert (e)end insert of Section 11165.

20(b)  Pharmacies may dispense prescriptions for Schedule III,
21Schedule IV, and Schedule V controlled substances from
22out-of-state prescribers pursuant to Section 4005 of the Business
23and Professions Code and Section 1717 of Title 16 of the California
24Code of Regulations.

25(c)  This section shall become operative on January 1, 2005.

26

begin deleteSEC. 4.end delete
27begin insertSEC. 5.end insert  

Section 11165 of the Health and Safety Code is
28amended to read:

29

11165.  

(a) To assist health care practitioners in their efforts
30to ensure appropriate prescribing, ordering, administering,
31furnishing, and dispensing of controlled substances, law
32enforcement and regulatory agencies in their efforts to control the
33diversion and resultant abuse of Schedule II, Schedule III, and
34Schedule IV controlled substances, and for statistical analysis,
35education, and research, the Department of Justice shall, contingent
36upon the availability of adequate funds in the CURES accounts
37within the Contingent Fund of the Medical Board of California,
38the Pharmacy Board Contingent Fund, the State Dentistry Fund,
39the Board of Registered Nursing Fund, the Naturopathic Doctor’s
40Fund, the Osteopathic Medical Board of California Contingent
P8    1Fund, the Veterinary Medical Board Contingent Fund, the
2Optometry Fund, the Board of Podiatric Medicine Fund, and the
3CURES Fund, maintain the Controlled Substance Utilization
4Review and Evaluation System (CURES) for the electronic
5monitoring of, and Internet access to information regarding, the
6prescribing and dispensing of Schedule II, Schedule III, and
7Schedule IV controlled substances by all practitioners authorized
8to prescribe, order, administer, furnish, or dispense these controlled
9substances.

10(b) The reporting of Schedule III and Schedule IV controlled
11substance prescriptions to CURES shall be contingent upon the
12availability of adequate funds for the Department of Justice for
13the purpose of funding CURES.

14(c) The Department of Justice may seek and use grant funds to
15pay the costs incurred by the operation and maintenance of
16CURES. The department shall annually report to the Legislature
17and make available to the public the amount and source of funds
18it receives for support of CURES. Grant funds shall not be
19appropriated from the Contingent Fund of the Medical Board of
20California, the Pharmacy Board Contingent Fund, the State
21Dentistry Fund, the Board of Registered Nursing Fund, the
22Naturopathic Doctor’s Fund, the Osteopathic Medical Board of
23California Contingent Fund, the Veterinary Medical Board
24Contingent Fund, the Optometry Fund, or the Board of Podiatric
25Medicine Fund, for the purpose of funding CURES.

26(d) (1) The operation of CURES shall comply with all
27applicable federal and state privacy and security laws and
28regulations.

29(2) The Department of Justice may establish policies,
30procedures, and regulations regarding the use, access, evaluation,
31management, implementation, operation, storage, and security of
32the information within CURES.

33(e) For each prescription for a Schedule II, Schedule III, or
34Schedule IV controlled substance, as defined in the controlled
35substances schedules in federal law and regulations, specifically
36Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21
37of the Code of Federal Regulations, the dispensing pharmacy,
38clinic, or other dispenser shall report the following information to
39the Department of Justice as soon as reasonably possible, but not
40more than seven days after the date a controlled substance is
P9    1dispensed, unless monthly reporting is permitted pursuant to
2subdivision (f) of Section 11190, and in a format specified by the
3Department of Justice:

4(1) Full name, address, and telephone number of the ultimate
5user or research subject, or contact information as determined by
6the Secretary of the United States Department of Health and Human
7Services, and the gender, and date of birth of the ultimate user.

8(2) The prescriber’s category of licensure and license number,
9the federal controlled substance registration number, and the state
10medical license number of any prescriber using the federal
11controlled substance registration number of a government-exempt
12facility.

13(3) Pharmacy prescription number, license number, and federal
14controlled substance registration number.

15(4) National Drug Code (NDC) number of the controlled
16substance dispensed.

17(5) Quantity of the controlled substance dispensed.

18(6) International Statistical Classification of Diseases, 9th
19revision (ICD-9) or 10th revision (ICD-10) Code, if available.

20(7) Number of refills ordered.

21(8) Whether the drug was dispensed as a refill of a prescription
22or as a first-time request.

23(9) Date of origin of the prescription.

24(10) Date of dispensing of the prescription.

25(f) The Department of Justice may invite stakeholders to assist,
26advise, and make recommendations on the establishment of rules
27and regulations necessary to ensure the proper administration and
28enforcement of the CURES database. All prescriber invitees shall
29be licensed by one of the boards or committees identified in
30 subdivision (a) of Section 805.8 of the Business and Professions
31Code, in active practice in California, and a regular user of CURES.

32(g) The Department of Justice shall, prior to upgrading CURES,
33consult with prescribers licensed by one of the boards or
34committees identified in subdivision (a) of Section 805.8 of the
35Business and Professions Code, one or more of the regulatory
36boards or committees identified in subdivision (a) of Section 805.8
37of the Business and Professions Code, and any other stakeholder
38identified by the department for the purpose of identifying desirable
39capabilities and upgrades to the CURES Prescription Drug
40Monitoring Program.

P10   1(h) The Department of Justice may establish a process to educate
2authorized subscribers of CURES on how to access and use
3 CURES.

4(i) The CURES Fund is hereby established within the State
5Treasury. The CURES Fund shall consist of all funds made
6available to the Department of Justice for the purpose of funding
7CURES. Money in the CURES Fund shall, upon appropriation by
8the Legislature, be available for allocation to the Department of
9Justice for the purpose of funding CURES.

10

begin deleteSEC. 5.end delete
11begin insertSEC. 6.end insert  

Section 11165.1 of the Health and Safety Code is
12amended to read:

13

11165.1.  

(a) (1) A licensed health care practitioner eligible
14to prescribe Schedule II, Schedule III, or Schedule IV controlled
15substances or a pharmacist shall submit an application developed
16by the Department of Justice to obtain approval to access
17information online regarding the controlled substance history of
18a patient that is stored on the Internet and maintained within the
19Department of Justice, and, upon approval, the department shall
20release to that practitioner or pharmacist the electronic history of
21controlled substances dispensed to an individual under his or her
22care based on data contained in the CURES Prescription Drug
23Monitoring Program (PDMP).

24(A) An application may be denied, or a subscriber may be
25suspended, for reasons which include, but are not limited to, the
26following:

27(i) Materially falsifying an application for a subscriber.

28(ii) Failure to maintain effective controls for access to the patient
29activity report.

30(iii) Suspended or revoked federal Drug Enforcement
31Administration (DEA) registration.

32(iv) Any subscriber who is arrested for a violation of law
33governing controlled substances or any other law for which the
34possession or use of a controlled substance is an element of the
35crime.

36(v) Any subscriber accessing information for any other reason
37than caring for his or her patients.

38(B) Any authorized subscriber shall notify the Department of
39Justice within 30 days of any changes to the subscriber account.

P11   1(2) To allow sufficient time for licensed health care practitioners
2eligible to prescribe Schedule II, Schedule III, or Schedule IV
3controlled substances and a pharmacist to apply and receive access
4to PDMP, a written request may be made, until July 1, 2012, and
5the Department of Justice may release to that practitioner or
6pharmacist the history of controlled substances dispensed to an
7individual under his or her care based on data contained in CURES.

8(b) Any request for, or release of, a controlled substance history
9pursuant to this section shall be made in accordance with guidelines
10developed by the Department of Justice.

11(c) (1) Until the Department of Justice has issued the
12notification described in paragraph (3), in order to prevent the
13inappropriate, improper, or illegal use of Schedule II, Schedule
14III, or Schedule IV controlled substances, the Department of Justice
15may initiate the referral of the history of controlled substances
16dispensed to an individual based on data contained in CURES to
17licensed health care practitioners, pharmacists, or both, providing
18care or services to the individual.

19(2) Upon the Department of Justice issuing the notification
20described in paragraph (3), licensed health care practitioners
21eligible to prescribe Schedule II, Schedule III, or Schedule IV
22controlled substances and pharmacists shall be strongly encouraged
23to access and consult the electronic history of controlled substances
24dispensed to an individual under his or her care prior to prescribing
25or dispensing a Schedule II, Schedule III, or Schedule IV controlled
26substance.

27(3) The Department of Justice shall notify licensed health care
28practitioners and pharmacists who have submitted the application
29required pursuant to subdivision (a) when the department
30determines that CURES is capable of accommodating all users,
31but not before June 1, 2015. The department shall provide a copy
32of the notification to the Secretary of State, the Secretary of the
33Senate, the Chief Clerk of the Assembly, and the Legislative
34Counsel, and shall post the notification on the department’s Internet
35Web site.

36(d) The history of controlled substances dispensed to an
37individual based on data contained in CURES that is received by
38a practitioner or pharmacist from the Department of Justice
39pursuant to this section shall be considered medical information
40subject to the provisions of the Confidentiality of Medical
P12   1Information Act contained in Part 2.6 (commencing with Section
256) of Division 1 of the Civil Code.

3(e) Information concerning a patient’s controlled substance
4history provided to a prescriber or pharmacist pursuant to this
5section shall include prescriptions for controlled substances listed
6in Sections 1308.12, 1308.13, and 1308.14 of Title 21 of the Code
7of Federal Regulations.

8begin insert

begin insertSEC. 7.end insert  

end insert

begin insertSection 11165.4 is added to the end insertbegin insertHealth and Safety
9Code
end insert
begin insert, to read:end insert

begin insert
10

begin insert11165.4.end insert  

(a) The Department of Justice may seek private funds
11from insurers, health care service plans, and qualified
12manufacturers for the purpose of supporting CURES. Insurers,
13health care service plans, and qualified manufacturers may
14contribute by submitting their payment to the Controller for deposit
15into the CURES Fund established pursuant to subdivision (e) of
16Section 11165. The department shall make information about the
17amount and the source of all private funds it receives for support
18of CURES available to the public. Contributions to the CURES
19Fund pursuant to this subdivision shall be nondeductible for state
20tax purposes.

21(b) For purposes of this section, the following definitions apply:

22(1) “Controlled substance” means a drug, substance, or
23immediate precursor listed in any schedule in Section 11055,
2411056, or 11057 of the Health and Safety Code.

25(2) “Health care service plan” means an entity licensed
26pursuant to the Knox-Keene Health Care Service Plan Act of 1975
27(Chapter 2.2 (commencing with Section 1340) of Division 2 of the
28Health and Safety Code).

29(3) “Insurer” means an admitted insurer writing health
30insurance, as defined in Section 106 of the Insurance Code, and
31an admitted insurer writing workers’ compensation insurance, as
32defined in Section 109 of the Insurance Code.

33(4) “Qualified manufacturer” means a manufacturer of a
34controlled substance, but does not mean a wholesaler or
35nonresident wholesaler of dangerous drugs, regulated pursuant
36to Article 11 (commencing with Section 4160) of Chapter 9 of
37Division 2 of the Business and Professions Code, a veterinary
38food-animal drug retailer, regulated pursuant to Article 15
39(commencing with Section 4196) of Chapter 9 of Division 2 of the
40Business and Professions Code, or an individual regulated by the
P13   1Medical Board of California, the Dental Board of California, the
2California State Board of Pharmacy, the Veterinary Medical
3Board, the Board of Registered Nursing, the Physician Assistant
4Committee of the Medical Board of California, the Osteopathic
5Medical Board of California, the State Board of Optometry, or
6the California Board of Podiatric Medicine.

end insert
begin delete
7

SEC. 6.  

Part 21 (commencing with Section 42001) is added to
8Division 2 of the Revenue and Taxation Code, to read:

9 

10PART 21.  Controlled Substance Utilization
11Review and Evaluation System (CURES) Tax Law

12

 

13

42001.  

For purposes of this part, the following definitions
14apply:

15(a) “Controlled substance” means a drug, substance, or
16immediate precursor listed in any schedule in Section 11055,
1711056, or 11057 of the Health and Safety Code.

18(b) “Health care service plan” means an entity licensed pursuant
19to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter
202.2 (commencing with Section 1340) of Division 2 of the Health
21and Safety Code).

22(c) “Insurer” means an admitted insurer writing health insurance,
23as defined in Section 106 of the Insurance Code, and an admitted
24insurer writing workers’ compensation insurance, as defined in
25Section 109 of the Insurance Code.

26(d) “Qualified manufacturer” means a manufacturer of a
27controlled substance, but does not mean a wholesaler or nonresident
28wholesaler of dangerous drugs, regulated pursuant to Article 11
29(commencing with Section 4160) of Chapter 9 of Division 2 of
30the Business and Professions Code, a veterinary food-animal drug
31retailer, regulated pursuant to Article 15 (commencing with Section
324196) of Chapter 9 of Division 2 of the Business and Professions
33Code, or an individual regulated by the Medical Board of
34California, the Dental Board of California, the California State
35Board of Pharmacy, the Veterinary Medical Board, the Board of
36Registered Nursing, the Physician Assistant Committee of the
37Medical Board of California, the Osteopathic Medical Board of
38California, the State Board of Optometry, or the California Board
39of Podiatric Medicine.

P14   1

42003.  

(a) Beginning January 1, 2015, for the privilege of
2doing business in this state, an annual tax is hereby imposed on
3all qualified manufacturers in an amount determined pursuant to
4Section 42007 for the purpose of establishing and maintaining
5enforcement of the Controlled Substance Utilization Review and
6Evaluation System (CURES), established pursuant to Section
711165 of the Health and Safety Code.

8(b) The Department of Justice may seek grant moneys from
9insurers and health care service plans for the purpose of supporting
10CURES. Insurers and health care service plans may contribute by
11submitting their payment to the Controller for deposit into the
12CURES Fund established pursuant to subdivision (e) of Section
1311165 of the Health and Safety Code. The department shall make
14information about the amount and the source of all private grant
15funds it receives for support of CURES available to the public. A
16grant or gift made to the CURES Fund pursuant to this subdivision
17shall be nondeductible for state tax purposes.

18

42005.  

(a) The board shall collect the annual tax imposed by
19this part pursuant to the Fee Collection Procedures Law (Part 30
20(commencing with Section 55001)). For purposes of this part, a
21reference in the Fee Collection Procedures Law to a “fee” shall
22include this tax and a reference to a “feepayer” shall include a
23person liable for the payment for the taxes collected pursuant to
24that law.

25(b) (1) The board shall not accept or consider a petition for
26redetermination that is based on the assertion that a determination
27by the Department of Justice incorrectly determined that a qualified
28manufacturer is subject to the tax or that a determination by the
29Department of Justice improperly or erroneously calculated the
30amount of that tax. The board shall forward to the Department of
31Justice any appeal of a determination that asserts that a
32determination by the Department of Justice incorrectly determined
33that a qualified manufacturer is subject to the tax or that a
34determination by the Department of Justice improperly or
35erroneously calculated the amount of that tax.

36(2) The board shall not accept or consider a claim for refund
37that is based on the assertion that a determination by the
38Department of Justice improperly or erroneously calculated the
39amount of a tax, or incorrectly determined that the qualified
40manufacturer is subject to the tax. The board shall forward to the
P15   1Department of Justice any claim for refund that asserts that a
2determination by the Department of Justice incorrectly determined
3that a qualified manufacturer is subject to the tax or that a
4determination by the Department of Justice improperly or
5erroneously calculated the amount of that tax.

6

42007.  

(a) The Department of Justice shall determine the
7annual tax by dividing the cost to establish and maintain
8enforcement of CURES by the number of qualified manufacturers.
9For calendar year 2015, the CURES cost shall be four million two
10hundred thousand dollars ($4,200,000). Beginning with the 2016
11calendar year, and for each calendar year thereafter, the Department
12of Justice shall adjust the rate annually to reflect increases or
13decreases in the cost of living during the prior fiscal year, as
14measured by the California Consumer Price Index for all items.

15(b) The Department of Justice shall provide to the board the
16name and address of each qualified manufacturer that is liable for
17the annual tax, the amount of tax, and the due date.

18(c) All annual taxes referred to the board for collection pursuant
19to Section 42005 shall be paid to the board.

20

42009.  

All taxes, interest, penalties, and other amounts
21collected pursuant to this part, less refunds and costs of
22administration, shall be deposited into the CURES Fund.

23

42011.  

The board shall prescribe, adopt, and enforce rules and
24regulations relating to the administration and enforcement of this
25part.

26

SEC. 7.  

No reimbursement is required by this act pursuant to
27Section 6 of Article XIII B of the California Constitution because
28the only costs that may be incurred by a local agency or school
29district will be incurred because this act creates a new crime or
30infraction, eliminates a crime or infraction, or changes the penalty
31for a crime or infraction, within the meaning of Section 17556 of
32the Government Code, or changes the definition of a crime within
33the meaning of Section 6 of Article XIII B of the California
34Constitution.

end delete
35

SEC. 8.  

This act is an urgency statute necessary for the
36immediate preservation of the public peace, health, or safety within
37the meaning of Article IV of the Constitution and shall go into
38immediate effect. The facts constituting the necessity are:

P16   1In order to protect the public from the continuing threat of
2prescription drug abuse at the earliest possible time, it is necessary
3that this act take effect immediately.



O

    95